Tralokinumab is an IL-13 specific human immunoglobulin G4 monoclonal antibody that binds to and neutralizes IL-13, which showed therapeutic advantage in clinical trials involving patients with asthma and idiopathic pulmonary fibrosis. The gene discussed is IL13; the disease is pulmonary fibrosis.